Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery - PubMed (original) (raw)
. 2014 May;1844(5):950-9.
doi: 10.1016/j.bbapap.2013.11.017. Epub 2013 Dec 19.
Affiliations
- PMID: 24361481
- DOI: 10.1016/j.bbapap.2013.11.017
Free article
Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery
Ramesh Ummanni et al. Biochim Biophys Acta. 2014 May.
Free article
Abstract
The reverse phase protein array (RPPA) approach was employed for a quantitative analysis of 71 cancer-relevant proteins and phosphoproteins in 84 non-small cell lung cancer (NSCLC) cell lines and by monitoring the activation state of selected receptor tyrosine kinases, PI3K/AKT and MEK/ERK1/2 signaling, cell cycle control, apoptosis, and DNA damage. Additional information on NSCLC cell lines such as that of transcriptomic data, genomic aberrations, and drug sensitivity was analyzed in the context of proteomic data using supervised and non-supervised approaches for data analysis. First, the unsupervised analysis of proteomic data indicated that proteins clustering closely together reflect well-known signaling modules, e.g. PI3K/AKT- and RAS/RAF/ERK-signaling, cell cycle regulation, and apoptosis. However, mutations of EGFR, ERBB2, RAF, RAS, TP53, and PI3K were found dispersed across different signaling pathway clusters. Merely cell lines with an amplification of EGFR and/or ERBB2 clustered closely together on the proteomic, but not on the transcriptomic level. Secondly, supervised data analysis revealed that sensitivity towards anti-EGFR drugs generally correlated better with high level EGFR phosphorylation than with EGFR abundance itself. High level phosphorylation of RB and high abundance of AURKA were identified as candidates that can potentially predict sensitivity towards the aurora kinase inhibitor VX680. Examples shown demonstrate that the RPPA approach presents a useful platform for targeted proteomics with high potential for biomarker discovery. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.
Keywords: Biomarker; Cancer genetics; NSCLC; RPPA; Reverse phase protein arrays; Targeted proteomics.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
- Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Matsubara D, et al. J Thorac Oncol. 2010 Sep;5(9):1317-24. doi: 10.1097/JTO.0b013e3181e2a409. J Thorac Oncol. 2010. PMID: 20736805 - Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Nanjundan M, et al. J Thorac Oncol. 2010 Dec;5(12):1894-904. doi: 10.1097/JTO.0b013e3181f2a266. J Thorac Oncol. 2010. PMID: 21124077 Free PMC article. - Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine.
Masuda M, Yamada T. Masuda M, et al. Biochim Biophys Acta. 2015 Jun;1854(6):651-7. doi: 10.1016/j.bbapap.2014.10.014. Epub 2014 Oct 27. Biochim Biophys Acta. 2015. PMID: 25448010 Review. - Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Brognard J, Dennis PA. Brognard J, et al. Cell Death Differ. 2002 Sep;9(9):893-904. doi: 10.1038/sj.cdd.4401054. Cell Death Differ. 2002. PMID: 12181740 - Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM, Wozniak A. Gadgeel SM, et al. Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332287 Review.
Cited by
- Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.
Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin EF 3rd, Pollard HB, Serrels B, Zhu J. Akbani R, et al. Mol Cell Proteomics. 2014 Jul;13(7):1625-43. doi: 10.1074/mcp.O113.034918. Epub 2014 Apr 28. Mol Cell Proteomics. 2014. PMID: 24777629 Free PMC article. - Toward a systems-level view of dynamic phosphorylation networks.
Newman RH, Zhang J, Zhu H. Newman RH, et al. Front Genet. 2014 Aug 15;5:263. doi: 10.3389/fgene.2014.00263. eCollection 2014. Front Genet. 2014. PMID: 25177341 Free PMC article. Review. - Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.
Emdal KB, Dittmann A, Reddy RJ, Lescarbeau RS, Moores SL, Laquerre S, White FM. Emdal KB, et al. Mol Cancer Ther. 2017 Nov;16(11):2572-2585. doi: 10.1158/1535-7163.MCT-17-0413. Epub 2017 Aug 22. Mol Cancer Ther. 2017. PMID: 28830985 Free PMC article. - An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.
Dutil J, Chen Z, Monteiro AN, Teer JK, Eschrich SA. Dutil J, et al. Cancer Res. 2019 Apr 1;79(7):1263-1273. doi: 10.1158/0008-5472.CAN-18-2747. Epub 2019 Mar 20. Cancer Res. 2019. PMID: 30894373 Free PMC article. Review. - Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.
Kaddi CD, Wang MD. Kaddi CD, et al. IEEE J Biomed Health Inform. 2017 Jan;21(1):246-253. doi: 10.1109/JBHI.2015.2489158. Epub 2015 Oct 8. IEEE J Biomed Health Inform. 2017. PMID: 26462248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous